Fenofibrate drug found to reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of good cholesterol, finds a new study funded by the National Heart, Lung, and Blood Institute (NHLBI).
The research study is published in the journal JAMA Cardiology.
‘Fenofibrate drug was found to reduce the risk of heart diseases in diabetes patient with high levels of triglycerides despite using statins.’
Fenofibrate is primarily used to help reduce elevated levels of triglycerides, or fat, in the blood. But the researchers wanted to know if the drug, when combined with statin treatment, could also reduce the risk of heart disease in people with type 2 diabetes. People with type 2 diabetes are at high risk of cardiovascular-related events, such as heart attacks, stroke, and even death, often because their levels of triglycerides are so high, and their high-density lipoprotein (HDL) cholesterol levels are low.
To answer their question, the researchers followed 4,640 participants from the NHLBI-funded Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study for five years after the conclusion of the trial in 2009. The findings suggest that fenofibrate therapy may be beneficial in the way the researchers hoped: by reducing cardiovascular events in patients with type 2 diabetes who take statins but still have especially high triglycerides levels and low HDL cholesterol levels. However, a randomized study is needed to confirm these findings, according to the authors.